Compare CFLT & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CFLT | ROIV |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 14.1B |
| IPO Year | 2021 | N/A |
| Metric | CFLT | ROIV |
|---|---|---|
| Price | $30.14 | $22.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 32 | 8 |
| Target Price | ★ $29.93 | $24.31 |
| AVG Volume (30 Days) | ★ 19.4M | 8.4M |
| Earning Date | 02-10-2026 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,113,149,000.00 | $20,329,000.00 |
| Revenue This Year | $22.76 | N/A |
| Revenue Next Year | $16.57 | $741.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.57 | N/A |
| 52 Week Low | $15.64 | $8.73 |
| 52 Week High | $37.90 | $23.47 |
| Indicator | CFLT | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 77.78 | 61.36 |
| Support Level | $29.95 | $21.60 |
| Resistance Level | $30.07 | $22.76 |
| Average True Range (ATR) | 0.16 | 0.84 |
| MACD | 0.07 | 0.04 |
| Stochastic Oscillator | 98.84 | 70.91 |
Confluent Inc provides a data streaming platform that enables customers to connect their applications, systems, and data layers and can be deployed as a fully managed cloud-native software-as-a-service (SaaS) offering. Its products include Confluent Cloud, a self-managed software offering, Confluent Platform, a managed service offering where the raw data resides inside a customer's cloud environment, and WarpStream, among others. Confluent also offers professional services and education services. The company generates revenue from the sale of subscriptions and services. Geographically, it generates a majority of its revenue from its business in the United States and the rest from International markets.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.